Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Translocon-associated protein subunit beta (SSR2)
- Target
- SSR2
- Molecular classification
- Receptor (specifically, endoplasmic reticulum membrane receptor), Component of the TRAP complex, Component of the translocon complex
01
Overview
Translocon-associated protein subunit beta (SSR2, also known as TRAP-beta) is a glycosylated, integral membrane protein that forms part of the signal sequence receptor (SSR) complex in the endoplasmic reticulum membrane. The SSR complex, composed of alpha-SSR (SSR1) and beta-SSR (SSR2), is involved in the co-translational translocation of nascent secretory and membrane proteins into the ER. In this process, SSR2 helps form a receptor for signal sequence-bearing proteins, aiding their passage through the Sec61 translocon channel into the ER lumen for subsequent folding and modification. While vital for appropriate protein secretion and maturation, current evidence suggests SSR2 is not a major independent drug target but rather a facilitator within the broader translocation machinery[5][6][7].
- Other names
- Signal sequence receptor subunit 2SSR2TRAP-betaTranslocon-associated protein subunit betaBeta-signal sequence receptor
02
Mechanism of action
Not established as a primary drug target, so no defined mechanisms of action for drugs are reported[7].
03
Biological functions
Protein translocation across the ER membraneProtein secretionSubstrate recognition in the ER import process
04
Disease associations
Other (currently, there is no strong evidence linking SSR2 to major disease categories like cancer, neurodegeneration, etc., but dysfunction in protein translocation and ER processing can potentially contribute to various disease states)
05
Safety considerations
No notable therapeutic challenges or safety concerns reported for modulating SSR2 specifically. However, perturbation in ER protein translocation can potentially affect cell viability and protein homeostasis[2].
Beyond the preview
Go deeper on Translocon-associated protein subunit beta (SSR2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Translocon-associated protein subunit beta (SSR2).